ENDRA Life Sciences Inc. (NDRA) earnings
NDRA earnings moved a median of -1.37% by the close. Quarterly and annual NDRA reports and results, each read against the price at its own news timestamp. Back to the NDRA overview →
28 measured NDRA earnings events.
Where these NDRA earnings landedvs 28 measured NDRA earnings reactions
| Middle 50% of NDRA earnings reactions | -7.99% to +5.21% |
|---|---|
| Median reaction (to close) | -1.37% |
| Measured reactions | 28 |
Point-in-time · zero look-ahead
Half of the 28 NDRA earnings events with a measured close landed between -7.99% and +5.21%; 46% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | +0.00% | +0.45% | |
| Form 10-Q ENDRA Life Sciences Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.45% | |
| ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | -0.60% | +8.20% | |
| Form 10-Q ENDRA Life Sciences Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.60% | +8.20% | |
| Form 10-K ENDRA Life Sciences Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +5.92% | |
| ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results | Press release | +0.00% | -10.02% | |
| Form 10-Q ENDRA Life Sciences Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -10.02% | |
| ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results | Press release | +0.00% | +6.35% | |
| Form 10-Q ENDRA Life Sciences Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +6.35% | |
| ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results | Press release | +5.21% | +5.21% | |
| Form 10-Q ENDRA Life Sciences Inc. For: Mar 31 | SEC filing · Form 10-Q | +5.21% | +5.21% | |
| Form 10-K/A ENDRA Life Sciences Inc. For: Dec 31 | SEC filing · Form 10-K | +8.03% | +21.33% | |
| Form 10-K ENDRA Life Sciences Inc. For: Dec 31 | SEC filing · Form 10-K | — | -6.82% | |
| Form 10-Q/A ENDRA Life Sciences Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.76% | -3.05% | |
| Form 10-Q ENDRA Life Sciences Inc. For: Sep 30 | SEC filing · Form 10-Q | +4.45% | +0.20% | |
| ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update | Press release | -1.59% | -13.36% | |
| Form NT 10-Q ENDRA Life Sciences Inc. For: Sep 30 | SEC filing · Form NT | +0.05% | -8.35% | |
| ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update | Press release | -3.20% | -8.69% | |
| Form 10-Q ENDRA Life Sciences Inc. For: Jun 30 | SEC filing · Form 10-Q | -6.69% | -8.45% | |
| ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14 | Press release | -4.93% | -6.34% | |
| ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update | Press release | +0.74% | -2.75% | |
| Form 10-Q ENDRA Life Sciences Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.74% | -2.75% | |
| ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024 | Press release | -0.78% | -6.36% | |
| Form 10-K ENDRA Life Sciences Inc. For: Dec 31 | SEC filing · Form 10-K | +0.22% | -10.22% | |
| ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024 | Press release | +0.00% | -7.86% | |
| ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | — | +2.38% | |
| Form 10-Q ENDRA Life Sciences Inc. For: Sep 30 | SEC filing · Form 10-Q | — | +2.38% | |
| ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023 | Press release | -3.83% | +0.00% |
Keep exploring
More NDRA: analyst actions → · SEC filings → · NDRA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Harvard Bioscience, Inc. (HBIO) | 183 | -0.30% | 43% |
| ELEKTA B SHS UNSP/ADR (EKTAY) | 182 | 0.00% | 17% |
| Cocrystal Pharma, Inc. (COCP) | 180 | 0.00% | 48% |
| BIO BLAST PHARMA LTD ORDINARY (ORPN) | 180 | 0.00% | 35% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.